BRAF and cancer: Increased MAP/ERK kinase (MEK) activity is a feature of many cancers, and is often triggered by missense mutations in BRAF and NRAS, two upstream oncogenes and potent regulators of Ras/Raf/Mek/ERK signaling (Cantwell-Dorris et al., 2011; Burotto et al., 2014).